Instrument Inactif

Autres langues Immunoprecise Antibodies Ltd Toronto S.E.

Actions

TQY

CA87588T2020

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform	22/04
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	12/04
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications	28/03
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments	20/03
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024	15/03
ImmunoPrecise Antibodies : Q3 2024 Earnings Presentation	14/03
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*	14/03
IMMUNOPRECISE ANTIBODIES : MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 - Form 6-K	14/03
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	14/03
ImmunoPrecise Antibodies : Q3 2024 Earnings Transcript	14/03
IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	08/03
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	07/03
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	06/03
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	06/03
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	06/03
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024	04/03
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024	15/12
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	14/12
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*	14/12
Top Premarket Gainers	13/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Immunoprecise Antibodies Ltd Toronto S.E.

Actions

TQY

CA87588T2020

Autres langues

Filtres